Sherlock Biosciences Acquired by OraSure Technologies

Gunderson Dettmer represented client Sherlock Biosciences, a global health company bringing next-generation diagnostics to consumers and healthcare providers, in its acquisition by OraSure Technologies, a leader in point-of-need and home diagnostic tests and sample management solutions.

This acquisition expands OraSure’s innovation pipeline with the addition of Sherlock’s molecular diagnostics platform, which is able to provide rapid results with strong sensitivity and specificity in a disposable format that is well-suited for over-the-counter usage. Sherlock’s first molecular self-test is for Chlamydia Trachomatis (CT) and Neisseria Gonorrhoeae (NG) which will expand OraSure’s portfolio of rapid diagnostics for sexually transmitted infections (STIs), subject to regulatory approvals.

In the announcement of the acquisition, OraSure President and CEO Carrie Eglinton Manner said, “The acquisition of Sherlock represents the next step in OTI’s innovation strategy. Sherlock brings valuable capabilities with an advanced molecular platform that aims to deliver lab-like accuracy in a format that expands access to diagnostic insights through convenient, effortless tests. We are excited to welcome Sherlock’s talented team to OTI and believe that Sherlock’s unique capabilities will contribute significantly to the expansion of our pipeline of diagnostic tests in infectious disease, sexual health, and beyond.”

The Gunderson Dettmer team was led by Tim Ehrlich and included Jim Hauser, Tim Kulis, Taylor Sarkaria, Sandra Lucero, Chris Sundquist, Joel Diamond, Tina Xu and Mark Macchi.

Companies
Sherlock Biosciences
OraSure Technologies